PUSH TO HALVE BREAST CANCER DEATHS

HISTORIC $25 MILLION GRANT

National Breast Cancer Foundation

COLLABORATIVE RESEARCH ACCELERATOR GRANT

The National Breast Cancer Foundation has announced a landmark $25 million investment - the largest in its history - awarding its first Collaborative Research Accelerator (CRA) Grant to a powerful local and international collaboration led by the Garvan Institute of Medical Research.

The 'AllClear' program funded by the inaugural CRA, is focused on stopping breast cancer recurrence, with the long-term goal to halve deaths from breast cancer.



Yale University School of Medicine

WashU Medicine

The University of Sydney

UNSW Australia

The University of Newcastle Australia

ACU Australian Catholic University

Breast Cancer Trials

AllClear is enabled by Garvan's strategic collaboration with St Vincent's Hospital Sydney and UNSW Sydney.

The AllClear team is a collaboration of nearly 60 researchers across seven leading research institutes and organisations, including Breast Cancer Trials, the University of Sydney, the University of Newcastle, together with world-renowned international partners including Yale and Washington University, and 11 hospitals across NSW.

The AllClear research program integrates the voices of people with lived experience of breast cancer, and ensures diverse representation from metropolitan, regional, rural, and multicultural communities.

"This Collaborative Research Accelerator Grant reflects our commitment to driving innovation, fostering collaboration, and accelerating progress toward the National Breast Cancer Foundation's vision of Zero Deaths from breast cancer. This is more than funding - it's a strategic catalyst for change, a powerful demonstration of Australia's research leadership, and a vital step toward saving lives."

National Breast Cancer Foundation Chair,
Adjunct Professor Helen Zorbas AO

More than **21,000** people will be diagnosed with breast cancer each year and around **3,300** Australians still die from the disease annually.

Around **15% of people will experience a recurrence of their breast cancer within 10 years**. However, recurrence can happen even decades later, and this return can be life-threatening.

"Our long-term goal is to reduce breast cancer deaths by half, by tackling one of the most complex and urgent challenges in the field – preventing breast cancer from returning. AllClear brings unprecedented collaboration to identify these 'seeds' of relapse early, develop tools to predict who is most at risk of relapse, and develop targeted therapies to eliminate these 'seeds' of relapse, before they reawaken and cause metastatic breast cancer."

Co-Director of the Cancer Plasticity and Dormancy Program and AllClear lead at the Garvan Institute of Medical Research, Associate Professor Christine Chaffer

"The AllClear study is unique in the extent of its collaboration/size and scale across all elements of the research translation pipeline and represents a true bench-to-bedside research program. It draws on the world's largest biobank of relapse samples and uses state-of-the-art technology. The information and learnings from AllClear could transform how breast cancer is understood and treated and help the understanding of other cancers, giving hope to more people."

Garvan Institute of Medical Research, Co-Director of the Cancer Plasticity and Dormancy Program and Lab head, Professor Peter Croucher

Published 2025

"This inaugural Collaborative Research Accelerator Grant represents a significant leap forward in breast cancer research. By bringing together the brightest minds from Australia and around the world, we're tackling one of the greatest challenges - stopping breast cancer recurrence."

National Breast Cancer Foundation CEO, Dr Cleola Anderiesz

DISSEMINATION, DORMANCY & RELAPSE

1 Identify 'seeds' of relapse early

2 Develop tools to predict who is most at risk of relapse

3 Develop targeted therapies to eliminate these 'seeds' of relapse

"This landmark investment allows us to use the full strength of Garvan's research from cutting-edge technologies, to expert knowledge in cancer, genomics and immunology. Together, these capabilities will turn discoveries into real-world impact, helping save lives from breast cancer. There's never been a more exciting time in breast cancer research."

Garvan Institute of Medical Research, Professor Benjamin Kile, Executive Director

As part of NBCF's *Pink Horizon Research Strategy*, the CRA Grants will:

SOLVE CRITICAL QUESTIONS

Tackle the toughest, unanswered questions in breast cancer that hold the key to ending deaths.

FOSTER COLLABORATION

Build a dynamic research ecosystem that unites Australian and global experts to pursue integrated long-term, high-impact research to transform outcomes and save lives of those affected by breast cancer.

ACCELERATE PROGRESS

Drive breast cancer research forward at a pace and scale that matches the urgency of achieving our vision of Zero Deaths from breast cancer.

National Breast Cancer Foundation

CONTACT US

w: nbcf.org.au **p:** 1300 708 763 **p:** info@nbcf.org.au